ASH 2019

Videos

BRAF Inhibitor Vemurafenib Combined With Obinutuzumab Effective

WM Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Phase 1b/2 Study of JNJ-4528 in Patients With R/R MM

Two Years Rituximab Maintenance vs. Observation After Bendamustine Plus Rituximab

CPI-0610 as Monotherapy or “Add-on” to Ruxolitinib

CXCR4 Mutational Status Does Not Impact Outcomes

Phase II Study of Nivolumab in Patients With R/R Peripheral T-Cell Lymphoma

Combined Ibrutinib and Venetoclax for First-Line Treatment

Acalabrutinib, Obinutuzumab, and Venetoclax in Treatment-Naive CLL

Promising First-Line Immunotherapy Findings in Hodgkin Lymphoma

ZUMA-1: Three-Year Survival Data

Daratumumab Plus Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone

Dose Optimization of Duvelisib in Patients With R/R Peripheral T-Cell Lymphoma

Tisagenlecleucel CAR T-Cell Therapy for Adults With DLBCL

A Data-Driven Database for Hematology Clinical Research Development

Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy

Depth of Response to Daratumumab, Lenalidomide, Bortezomib and Dexamethasone Improves Over Time

Daratumumab Maintenance Therapy Improves Depth of Response and Results in Durable PFS

Phase I Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory CLL / SLL

Updates From the Phase III MURANO Study

Complete Coverage

A doctor comforts a young patient before chemotherapy.

Evidence Supports Outpatient Management of Some Children With AML Undergoing Intensive Chemotherapy

Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.

Providing the patient and caregiver a course of care.

High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCL

Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.

A study affirmed the benefits of a multimodal approach in the assessment of minimal residual disease in multiple myeloma.

Inhibiting BCMA Antigen Loss May Enhance BCMA-Directed CAR-T Therapy in R/R MM

A putative mechanism of resistance to BCMA-directed CAR-T therapy involves BCMA antigen loss through cleavage of BCMA from the surface of myeloma cells.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

Delving Into the Genomic/Transcriptomic Landscape of Follicular Lymphoma

Little is currently known about how molecular alterations interact in the oncogenesis of follicular lymphoma.

Long-Term Disease Control With Dose-Intensified Regimen in Lymphoma

For patients with early unfavorable Hodgkin lymphoma, disease control was improved with a dose-intensified regimen, but no overall survival gain was seen.

Medicare Paid Some Docs $3 Million Each in 2012

Real-World Data Show Higher Economic, AE Burden of CLL

Addressing increased adverse events could be unmet medical need for Medicare-aged patients.

Hairy Cell Leukemias Responded to Vemurafenib-Obinutuzumab Combination

Combining vemurafenib with obinutuzumab in patients with relapsed or refractory HCL resulted in a complete response rate of 100% in the frontline setting.

From 2004 to 2009, marked increase in observation among men with low-risk prostate cancer.

Blinatumomab May Become New Standard of Care for Post-Reinduction Therapy in Young Patients With B-ALL

Although allogeneic HSCT is considered the treatment of choice for patients with relapsed B-ALL, a number of potential barriers to its implementation can exist.

There appears to be accumulating evidence to support the routine use of busulfan plus melphalan as a conditioning regimen.

Postremission Oral Azacitidine Maintenance Therapy Proposed As a New Standard of Care in Some Patients With AML

Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.

Tirabrutinib Shows Promise in Waldenström Macroglobulinemia

The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).

The results of this study support previous findings that psychological distress is associated with a

Temporal Trends in the Diagnosis and Treatment of Patients With Waldenström Macroglobulinemia

Many of the patients with WM included in this retrospective study had received multiple lines of treatment.

Biomarker detects early-stage lung cancer.

Inotuzumab Ozogamicin Shows Clinical Efficacy in Relapsed Pediatric B-ALL

Inotuzumab ozogamicin (InO) exhibits clinical efficacy against heavily pretreated, relapsed CD22-positive pediatric B-cell acute lymphoblastic leukemia (B-ALL).

Better Short-Term QoL, Fewer Symptoms With CAR-T vs SCT in Hematologic Malignancies

While PRO-CTCAEs capture patient reports of particular symptomatic AEs, the “toxicity over time” approach provides a longitudinal assessment of these AEs.